With Arena Pharmaceuticals (ARNA) and Eisai still waiting for their obesity drug Belviq to complete DEA scheduling, it was their chief rival VIVUS (VVUS) that made news today. All eyes were on VIVUS' decision to take out a loan that could amount to $110 million.
But why is this necessary at all? Does the company need more capital to enhance its marketing strategy for the obesity drug Qsymia, or is this a signal that VIVUS is currently in a difficult financial situation? Health-care analyst Max Macaluso sheds light on this news in the following video.
